Table F.1.

Antimicrobials reported, methods used, type of data reported and interpretive criteria applied by MSs for human Salmonella AST data in 2020

Country	Gentamicin	Chloramphenicol	Ampicillin	Cefotaxime	Ceftazidime	Meropenem	Tigecycline	Nalidixic acid	Ciprofloxacin/pefloxacin	Azithromycin	Colistin	Sulfonamides	Trimethoprim	Trimethoprim‐sulfa	Tetracyclines	Method used	Quantitative (Q) or categorical (SIR or PWT/PNWT)	Interpretive criteria
Austria	●	●	●	●	●	●	●	●	●( a )	●		●	●		●	DD	Q	Interpreted by ECDC. EUCAST ECOFFs for all except CLSI CBP for SUL
Belgium	●	●	●	●		●	●		●			●	●		●	DL	Q	Interpreted by ECDC, as for Austria. EFSA criteria for AZM MIC
Cyprus	●		●	●	●	●			●		●			●		DL/DLG	Q	Interpreted by ECDC, as for Austria, except for CTX, MEM and SXT where EUCAST CBP were used
Denmark	●	●	●	●	●	●	●	●	●	●	●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria. EFSA criteria for AZM MIC
Estonia	●	●	●	●	●	●	●	●	●		●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria
Finland	●	●	●	●		●		●	●( a )				●		●	DD	Q	Interpreted by ECDC, as for Austria
France	●	●	●	●	●	●	●	●	●	●	●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria. EFSA criteria for AZM MIC
Hungary	●	●	●	●	●	●			●( a )				●	●	●	DD	SIR	EUCAST CBP except CLSI CBP for NAL, SUL and TET
Iceland			●	●					●( a )					●		DD	SIR	EUCAST CBP
Ireland	●	●	●	●		●			●	●	●	●	●		●	WGS	PWT/PNWT	Sequencing results interpreted by the laboratory with BioNumerics tools for acquired AMR genes and point mutations
Italy	●	●	●	●	●	●	●	●	●( a )	●	●	●	●		●	DD/DL	Q	Interpreted by ECDC, as for Austria
Latvia			●						●					●		DD	SIR	No recent information on guidelines used
Luxembourg	●	●	●	●	●	●			●( a )		●	●		●	●	DD/DL/DLG	Q	Interpreted by ECDC, as for Austria
Malta	●		●	●	●	●			●							DL/DLG/DD	Q	Interpreted by ECDC, as for Austria
Netherlands	●	●	●	●	●	●	●	●	●	●	●	●	●		●	DL	Q	Interpreted by ECDC, as for Austria. EFSA criteria for AZM MIC
Norway		●	●	●	●	●			●( a )						●	DD	Q	Interpreted by ECDC, as for Austria
Portugal	●	●	●	●	●	●	●	●	●( a )	●		●	●		●	DD	Q	Interpreted by ECDC, as for Austria
Romania	●	●	●	●	●	●		●	●( a )			●	●	●	●	DD	Q	Interpreted by ECDC, as for Austria
Slovakia		●	●	●	●	●			●					●	●	DD/DL	SIR	EUCAST CBP except CLSI CBP for NAL, SUL and TET
Slovenia	●	●	●	●	●	●			●( a )			●	●	●	●	DD/DLG	Q	Interpreted by ECDC, as for Austria
Spain	●	●	●	●	●	●		●	●( a )			●	●		●	DD	Q	Interpreted by ECDC, as for Austria
Sweden	●	●	●	●	●	●	●		●	●	●	●	●		●	WGS	PWT/PNWT	Sequencing results interpreted by the laboratory with NCBI AMRFinder and CGE ResFinder and PointFinder

AST: antimicrobial susceptibility testing; CBP: clinical breakpoint; DD: disk diffusion; DL: dilution; DLG: dilution with gradient strip; WGS: whole genome sequencing; Q: quantitative data; SIR: susceptible standard dosing regimen, susceptible increased exposure, resistant (categorical data); PWT/PNWT: predicted wild type/predicted non‐wild type (categorical); ECDC: European Centre for Disease Prevention and Control; ECOFF: epidemiological cut‐off; CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; NCBI: National Center for Biotechnology Information, US; CGE: Center for Genomic Epidemiology, Denmark; MIC: minimum inhibitory concentration.

AZM: azithromycin; CTX: cefotaxime; GEN: gentamicin; MEM: meropenem; NAL: nalidixic acid; SUL: sulfonamides; TET: tetracycline.

^(a)Pefloxacin used in disk diffusion.